ArticleFrontiers in medicine2026
Siglec-5 suppresses LPS-induced acute lung injury via negative regulation of HSF1/SYK-mediated ROS production and pyroptosis.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the protective effect of Siglec-5 on lung injury in septic mice and its molecular mechanism. Methods: Forty-eight male SPF-grade ICR mice were randomly divided into the sham group, Model group (induced by LPS), Siglec5-OE group, and Siglec5-OE + SIRPα-OE group. After modeling, HE staining was used to evaluate pathological changes in lung tissue. ELISA was employed to measure the levels of MDA, SOD, GPX, IL-1β, IL-18, and GSDMD. RAW264.7 cells were treated with drugs, and Western blot was used to detect protein expression. Flow cytometry was performed to assess apoptosis, fluorescent probes were used to measure ROS fluorescence intensity, and immunofluorescence was used to detect NLRP3 fluorescence intensity. Results: Compared with the sham group, the Model group showed severe lung tissue damage, increased levels of MDA, IL-1β, IL-18, and GSDMD, and decreased levels of SOD and GPX. Compared with the Model group, the Siglec5-OE group exhibited improved lung injury, reduced levels of MDA, IL-1β, IL-18, and GSDMD, and increased levels of SOD and GPX. Compared with the Siglec5-OE group, the Siglec5-OE + SIRPα-OE group showed significantly aggravated lung tissue damage, increased levels of MDA, IL-1β, IL-18, and GSDMD, and decreased levels of SOD and GPX. Conclusion: Siglec-5 inhibits LPS-induced lung injury by regulating the HSF1/SYK/ERK1/2/SIRPα signaling pathway, thereby modulating ROS and pyroptosis responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.